<ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
<p>百时美施贵宝公司（NYSE:BMY - 免费报告）- 威廉·布莱尔的投资分析师在 9 月 2 日星期二发布的报告中上调了对百时美施贵宝 2028 财年每股收益（EPS）的预期。威廉·布莱尔的分析师 M. Phipps 现在预计这家生物制药公司将发布 5.67 美元的每股收益，高于他们之前的 5.61 美元预期。市场普遍预计百时美施贵宝当前全年的每股收益为 6.74 美元。</p>
<p>其他一些股票研究分析师也最近对该公司发表了评论。摩根士丹利在 7 月 31 日星期四的研究报告中重申了对百时美施贵宝的 “持有” 评级。大和美国在 8 月 5 日星期二的研究报告中将百时美施贵宝的评级从 “强力买入” 下调至 “持有”。华尔街 Zen 在 6 月 6 日星期五的研究报告中将百时美施贵宝的评级从 “强力买入” 下调至 “买入”。大和资本市场在 8 月 5 日星期二的研究报告中将百时美施贵宝的评级从 “跑赢大盘” 下调至 “中性”，并设定了 42.00 美元的目标价。最后，花旗集团在 8 月 1 日星期五的研究报告中将百时美施贵宝的目标价从 51.00 美元下调至 47.00 美元，并对该股票设定了 “中性” 评级。一位分析师给予该股票 “强力买入” 评级，四位给予 “买入” 评级，十五位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的当前共识评级为 “持有”，共识目标价为 56.38 美元。</p>
<p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
<ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
<p><strong>查看我们关于百时美施贵宝的最新股票报告</strong></p>
<h2>百时美施贵宝价格表现</h2>
<p>NYSE:BMY 在星期四开盘价为 47.48 美元。百时美施贵宝的 52 周低点为 42.96 美元，52 周高点为 63.33 美元。该公司的速动比率为 1.11，流动比率为 1.21，债务与股本比率为 2.54。该股票的市值为 966.4 亿美元，市盈率为 19.14，市盈增长比率为 2.41，贝塔值为 0.35。该股票的 50 日移动平均价格为 47.08 美元，200 日移动平均价格为 50.61 美元。</p>
<ul>
<li>百时美施贵宝的疲软指引可能正在创造机会</li>
</ul>
<p>百时美施贵宝（NYSE:BMY - 获取免费报告）最后一次公布季度收益结果是在 7 月 31 日星期四。这家生物制药公司报告本季度每股收益为 1.46 美元，超出市场普遍预期的 1.07 美元，超出 0.39 美元。该公司本季度的收入为 122.7 亿美元，而市场普遍预期为 113.2 亿美元。百时美施贵宝的股本回报率为 80.04%，净利润率为 10.58%。该公司的季度收入较去年同期增长了 0.6%。去年同期，该公司每股收益为 2.07 美元。百时美施贵宝已将其 2025 财年的指引设定为 6.350-6.650 美元每股收益。</p>
<h2>百时美施贵宝宣布分红</h2>
<p>该公司最近还披露了季度分红，分红于 8 月 1 日星期五支付。7 月 3 日星期四的登记投资者获得了 0.62 美元的分红。这代表着每年 2.48 美元的分红和 5.2% 的收益率。除息日期为 7 月 3 日星期四。百时美施贵宝的派息比率目前为 100.00%。</p>
<h2>百时美施贵宝的内部交易</h2>
<p>在相关消息中，执行副总裁 David V. Elkins 在 9 月 2 日星期二的交易中出售了 56,000 股百时美施贵宝的股票。该股票以平均价格 47.33 美元出售，总价值为 2,650,480.00 美元。出售后，该执行副总裁直接持有公司 167,379 股股票，价值约为 7,922,048.07 美元。此次交易使其持股减少了 25.07%。该交易已在向 SEC 提交的文件中披露，文件可通过此超链接访问。内部人士持有公司股票的 0.07%。</p>
<h2>机构投资者对百时美施贵宝的看法</h2>
<p>几家机构投资者最近买入和卖出了 BMY 的股票。Brighton Jones LLC 在第四季度将其在百时美施贵宝的持股增加了 33.4%。Brighton Jones LLC 现在拥有 19,728 股这家生物制药公司的股票，价值 1,116,000 美元，此前在上个季度又购买了 4,935 股。Pictet &amp; Cie Europe AG 在第四季度购买了百时美施贵宝的新头寸，价值约为 13,094,000 美元。Cary Street Partners Financial LLC 在第四季度购买了百时美施贵宝的新头寸，价值约为 2,301,000 美元。BOKF NA 在第四季度将其在百时美施贵宝的持股增加了 1.4%。BOKF NA 现在拥有 103,029 股这家生物制药公司的股票，价值 5,752,000 美元，此前在上个季度又购买了 1,464 股。最后，Centiva Capital LP 在第四季度将其在百时美施贵宝的持股增加了 8.7%。Centiva Capital LP 现在拥有 19,671 股这家生物制药公司的股票，价值 1,113,000 美元，此前在上个季度又购买了 1,580 股。目前 76.41% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于百时美施贵宝</h2>
<p>（获取免费报告）</p>
<p>百时美施贵宝公司在全球范围内发现、开发、许可、制造、营销、分销和销售生物制药产品。它提供针对血液学、肿瘤学、心血管、免疫学、纤维化和神经科学疾病的产品。公司的产品包括 Eliquis，用于降低非瓣膜性心房颤动患者中风/全身栓塞的风险，以及治疗深静脉血栓/DVT/肺栓塞/PE；Opdivo，用于多种抗癌适应症，包括膀胱癌、血液癌、结直肠癌、头颈癌、肾细胞癌、肝细胞癌、肺癌、黑色素瘤、胸膜间皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用于多发性骨髓瘤；Orencia 用于活动性类风湿关节炎和银屑病关节炎；Sprycel 用于治疗费城染色体阳性慢性髓性白血病。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过百时美施贵宝</li>
<li>投资高市盈率成长股</li>
<li>ETF 的回报：3 个可能继续表现优异的名字</li>
<li>什么是支撑位？</li>
<li>开学购物达到 400 亿美元：3 只值得关注的零售股票</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
<li>谷歌母公司股票在躲避严厉反垄断措施后大幅上涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在百时美施贵宝吗？</h2>
<p>在考虑百时美施贵宝之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而百时美施贵宝并不在名单上。</p>
<p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

百时美施贵宝

<p>威廉·布莱尔的投资分析师将百时美施贵宝（NYSE:BMY）2028 财年的每股收益（EPS）预估从 5.61 美元上调至 5.67 美元。该公司当前全年的每股收益共识预估为 6.74 美元。近期，多位分析师调整了对该股票的评级，其中包括一项强烈买入、四项买入、十五项持有和一项卖出。该股票开盘价为 47.48 美元，市值为 966.4 亿美元，市盈率为 19.14。百时美施贵宝还宣布了每季度 0.62 美元的股息，收益率为 5.2%</p>

<ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
</div><p>Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Investment analysts at William Blair lifted their FY2028 earnings per share (EPS) estimates for shares of Bristol Myers Squibb in a report released on Tuesday, September 2nd. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings per share of $5.67 for the year, up from their previous estimate of $5.61. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share.</p>
<div class="lb-trans"><p>百时美施贵宝公司（NYSE:BMY - 免费报告）- 威廉·布莱尔的投资分析师在 9 月 2 日星期二发布的报告中上调了对百时美施贵宝 2028 财年每股收益（EPS）的预期。威廉·布莱尔的分析师 M. Phipps 现在预计这家生物制药公司将发布 5.67 美元的每股收益，高于他们之前的 5.61 美元预期。市场普遍预计百时美施贵宝当前全年的每股收益为 6.74 美元。</p>
</div><p>A number of other equities research analysts have also recently commented on the company. Morgan Stanley restated a &#34;hold&#34; rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Daiwa America cut Bristol Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, August 5th. Wall Street Zen cut Bristol Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Friday, June 6th. Daiwa Capital Markets cut Bristol Myers Squibb from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $42.00 target price on the stock. in a research report on Tuesday, August 5th. Finally, Citigroup dropped their target price on Bristol Myers Squibb from $51.00 to $47.00 and set a &#34;neutral&#34; rating on the stock in a research report on Friday, August 1st. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $56.38.</p>
<div class="lb-trans"><p>其他一些股票研究分析师也最近对该公司发表了评论。摩根士丹利在 7 月 31 日星期四的研究报告中重申了对百时美施贵宝的 “持有” 评级。大和美国在 8 月 5 日星期二的研究报告中将百时美施贵宝的评级从 “强力买入” 下调至 “持有”。华尔街 Zen 在 6 月 6 日星期五的研究报告中将百时美施贵宝的评级从 “强力买入” 下调至 “买入”。大和资本市场在 8 月 5 日星期二的研究报告中将百时美施贵宝的评级从 “跑赢大盘” 下调至 “中性”，并设定了 42.00 美元的目标价。最后，花旗集团在 8 月 1 日星期五的研究报告中将百时美施贵宝的目标价从 51.00 美元下调至 47.00 美元，并对该股票设定了 “中性” 评级。一位分析师给予该股票 “强力买入” 评级，四位给予 “买入” 评级，十五位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的当前共识评级为 “持有”，共识目标价为 56.38 美元。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
</div><p><strong>View Our Latest Stock Report on Bristol Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>查看我们关于百时美施贵宝的最新股票报告</strong></p>
</div><h2>Bristol Myers Squibb Price Performance</h2>
<div class="lb-trans"><h2>百时美施贵宝价格表现</h2>
</div><p>NYSE:BMY opened at $47.48 on Thursday. Bristol Myers Squibb has a 52 week low of $42.96 and a 52 week high of $63.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The stock has a market capitalization of $96.64 billion, a PE ratio of 19.14, a price-to-earnings-growth ratio of 2.41 and a beta of 0.35. The stock's 50-day moving average price is $47.08 and its 200-day moving average price is $50.61.</p>
<div class="lb-trans"><p>NYSE:BMY 在星期四开盘价为 47.48 美元。百时美施贵宝的 52 周低点为 42.96 美元，52 周高点为 63.33 美元。该公司的速动比率为 1.11，流动比率为 1.21，债务与股本比率为 2.54。该股票的市值为 966.4 亿美元，市盈率为 19.14，市盈增长比率为 2.41，贝塔值为 0.35。该股票的 50 日移动平均价格为 47.08 美元，200 日移动平均价格为 50.61 美元。</p>
</div><ul>
<li>Weak Guidance from Bristol-Myers Could Be Creating an Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>百时美施贵宝的疲软指引可能正在创造机会</li>
</ul>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm's revenue for the quarter was up .6% compared to the same quarter last year. During the same period last year, the firm earned $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS.</p>
<div class="lb-trans"><p>百时美施贵宝（NYSE:BMY - 获取免费报告）最后一次公布季度收益结果是在 7 月 31 日星期四。这家生物制药公司报告本季度每股收益为 1.46 美元，超出市场普遍预期的 1.07 美元，超出 0.39 美元。该公司本季度的收入为 122.7 亿美元，而市场普遍预期为 113.2 亿美元。百时美施贵宝的股本回报率为 80.04%，净利润率为 10.58%。该公司的季度收入较去年同期增长了 0.6%。去年同期，该公司每股收益为 2.07 美元。百时美施贵宝已将其 2025 财年的指引设定为 6.350-6.650 美元每股收益。</p>
</div><h2>Bristol Myers Squibb Announces Dividend</h2>
<div class="lb-trans"><h2>百时美施贵宝宣布分红</h2>
</div><p>The company also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.2%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb's payout ratio is presently 100.00%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，分红于 8 月 1 日星期五支付。7 月 3 日星期四的登记投资者获得了 0.62 美元的分红。这代表着每年 2.48 美元的分红和 5.2% 的收益率。除息日期为 7 月 3 日星期四。百时美施贵宝的派息比率目前为 100.00%。</p>
</div><h2>Insider Transactions at Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>百时美施贵宝的内部交易</h2>
</div><p>In related news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.07% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 David V. Elkins 在 9 月 2 日星期二的交易中出售了 56,000 股百时美施贵宝的股票。该股票以平均价格 47.33 美元出售，总价值为 2,650,480.00 美元。出售后，该执行副总裁直接持有公司 167,379 股股票，价值约为 7,922,048.07 美元。此次交易使其持股减少了 25.07%。该交易已在向 SEC 提交的文件中披露，文件可通过此超链接访问。内部人士持有公司股票的 0.07%。</p>
</div><h2>Institutional Investors Weigh In On Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>机构投资者对百时美施贵宝的看法</h2>
</div><p>Several institutional investors have recently bought and sold shares of BMY. Brighton Jones LLC lifted its stake in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after purchasing an additional 4,935 shares in the last quarter. Bank Pictet &amp; Cie Europe AG purchased a new position in Bristol Myers Squibb in the 4th quarter worth approximately $13,094,000. Cary Street Partners Financial LLC purchased a new position in Bristol Myers Squibb in the 4th quarter worth approximately $2,301,000. BOKF NA lifted its stake in Bristol Myers Squibb by 1.4% in the 4th quarter. BOKF NA now owns 103,029 shares of the biopharmaceutical company's stock worth $5,752,000 after purchasing an additional 1,464 shares in the last quarter. Finally, Centiva Capital LP lifted its stake in Bristol Myers Squibb by 8.7% in the 4th quarter. Centiva Capital LP now owns 19,671 shares of the biopharmaceutical company's stock worth $1,113,000 after purchasing an additional 1,580 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家机构投资者最近买入和卖出了 BMY 的股票。Brighton Jones LLC 在第四季度将其在百时美施贵宝的持股增加了 33.4%。Brighton Jones LLC 现在拥有 19,728 股这家生物制药公司的股票，价值 1,116,000 美元，此前在上个季度又购买了 4,935 股。Pictet &amp; Cie Europe AG 在第四季度购买了百时美施贵宝的新头寸，价值约为 13,094,000 美元。Cary Street Partners Financial LLC 在第四季度购买了百时美施贵宝的新头寸，价值约为 2,301,000 美元。BOKF NA 在第四季度将其在百时美施贵宝的持股增加了 1.4%。BOKF NA 现在拥有 103,029 股这家生物制药公司的股票，价值 5,752,000 美元，此前在上个季度又购买了 1,464 股。最后，Centiva Capital LP 在第四季度将其在百时美施贵宝的持股增加了 8.7%。Centiva Capital LP 现在拥有 19,671 股这家生物制药公司的股票，价值 1,113,000 美元，此前在上个季度又购买了 1,580 股。目前 76.41% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>关于百时美施贵宝</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>百时美施贵宝公司在全球范围内发现、开发、许可、制造、营销、分销和销售生物制药产品。它提供针对血液学、肿瘤学、心血管、免疫学、纤维化和神经科学疾病的产品。公司的产品包括 Eliquis，用于降低非瓣膜性心房颤动患者中风/全身栓塞的风险，以及治疗深静脉血栓/DVT/肺栓塞/PE；Opdivo，用于多种抗癌适应症，包括膀胱癌、血液癌、结直肠癌、头颈癌、肾细胞癌、肝细胞癌、肺癌、黑色素瘤、胸膜间皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用于多发性骨髓瘤；Orencia 用于活动性类风湿关节炎和银屑病关节炎；Sprycel 用于治疗费城染色体阳性慢性髓性白血病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Return of the ETFs: 3 Names That Could Keep Outperforming</li>
<li>What is a support level?</li>
<li>Back-to-School Shopping Hits $40B: 3 Retail Stocks to Watch Now</li>
<li>Best Energy Stocks - Energy Stocks to Buy Now</li>
<li>Alphabet Stock Surges After Dodging Harsh Antitrust Remedies</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过百时美施贵宝</li>
<li>投资高市盈率成长股</li>
<li>ETF 的回报：3 个可能继续表现优异的名字</li>
<li>什么是支撑位？</li>
<li>开学购物达到 400 亿美元：3 只值得关注的零售股票</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
<li>谷歌母公司股票在躲避严厉反垄断措施后大幅上涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在百时美施贵宝吗？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑百时美施贵宝之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而百时美施贵宝并不在名单上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

研究分析师发布了关于百时美施贵宝 2028 财年收益的预测